Aquestive Therapeutics To Take A Leap With New Seizures clusters Drug

Earnings Per Share AQST has a market cap of $304 and an EPS of -1.76. While its historical trading records might not be glowing, its outlook is promising. Its current stock price is $9.05 and a peak of $33 is projected in a year from now. The recommendation is Strong Buy for AQST Other AQST had been in the news recently when it announced FDA’s decision to accept an NDA for its refractory and seizure clusters treatment called Libervant. The Prescription Drug User Fee Act review date is Month -end September 2020. A medical comparison of AQST’s with a recently approved cluster seizure medication in January, the VALTOCO and two other available options showed that the AQST has a proven therapeutic value otherwise it would not have got a waiver over the expected 7-year exclusivity period given to VALTOCO. Libervant sterling projection as the first diazepam product to be nationally available for to ARRS patients, opens a possible $300 million revenue outlook for AQST. Earnings Growth It will be right to consider Libervant is a buy-stock right now with market analysts accepting that it could do a 300-percent move over a 12 -month period after its launch

back

Aquestive Therapeutics To Take A Leap With New Seizures clusters Drug

bullish
Earnings Per Share AQST has a market cap of $304 and an EPS of -1.76. While its historical trading records might not be glowing, its outlook is promising. Its current stock price is $9.05 and a peak of $33 is projected in a year from now. The recommendation is Strong Buy for AQST Other AQST had been in the news recently when it announced FDA’s decision to accept an NDA for its refractory and seizure clusters treatment called Libervant. The Prescription Drug User Fee Act review date is Month -end September 2020. A medical comparison of AQST’s with a recently approved cluster seizure medication in January, the VALTOCO and two other available options showed that the AQST has a proven therapeutic value otherwise it would not have got a waiver over the expected 7-year exclusivity period given to VALTOCO. Libervant sterling projection as the first diazepam product to be nationally available for to ARRS patients, opens a possible $300 million revenue outlook for AQST. Earnings Growth It will be right to consider Libervant is a buy-stock right now with market analysts accepting that it could do a 300-percent move over a 12 -month period after its launch
Comments

Write your comment....

Sign in to comment

read-time
1 min

17.00

Target Price

9/ 10

Confidence

2-4 Weeks

Timeframe
Share
catalyst icon
Earnings Per Share
catalyst icon
Financials
catalyst icon
Management
catalyst icon
Price to Earnings Ratio
catalyst icon
Dividend
catalyst icon
Other Catalyst

AQST Channel

Start new chat
aiodd-ad
next